A Phase II, Randomized, Open Label Study of Single Dose siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer

Trial Profile

A Phase II, Randomized, Open Label Study of Single Dose siG12D LODER in Combination With Chemotherapy in Patients With Unresectable Locally Advanced Pancreatic Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Antisense K-ras RNA gene therapy (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Irinotecan; Oxaliplatin
  • Indications Pancreatic cancer
  • Focus Therapeutic Use
  • Sponsors Silenseed
  • Most Recent Events

    • 18 Oct 2016 Planned number of patients changed from 124 to 80.
    • 18 Oct 2016 Planned End Date changed from 1 Nov 2018 to 1 Jun 2020.
    • 18 Oct 2016 Planned primary completion date changed from 1 Nov 2017 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top